CONCORDBIO

Concord Biotech Share Price

₹1,650.20 -27.8 (-1.66%)

22 Feb, 2025 21:50

SIP TrendupStart SIP in CONCORDBIO

Start SIP

Performance

  • Low
  • ₹1,632
  • High
  • ₹1,693
  • 52 Week Low
  • ₹1,327
  • 52 Week High
  • ₹2,664
  • Open Price₹1,677
  • Previous Close₹1,678
  • Volume109,044

Investment Returns

  • Over 1 Month -23.62%
  • Over 3 Month -17.13%
  • Over 6 Month + 2.53%
  • Over 1 Year + 14.33%
SIP Lightning

Smart Investing Starts Here Start SIP with Concord Biotech for Steady Growth!

Invest Now

Concord Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 52.9
  • PEG Ratio
  • 7.4
  • Market Cap Cr
  • 17,264
  • P/B Ratio
  • 10.9
  • Average True Range
  • 129.03
  • EPS
  • 31.19
  • Dividend Yield
  • 0.5
  • MACD Signal
  • -68.7
  • RSI
  • 28.78
  • MFI
  • 27.7

Concord Biotech Financials

Concord Biotech Technicals

EMA & SMA

Current Price
₹1,650.20
-27.8 (-1.66%)
pointer
  • stock-down_img
  • Bearish Moving Average 16
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹1,953.90
  • 50 Day
  • ₹2,044.95
  • 100 Day
  • ₹2,015.14
  • 200 Day
  • ₹1,876.50

Resistance and Support

1658.38 Pivot Speed
  • R3 1,745.72
  • R2 1,719.33
  • R1 1,684.77
  • S1 1,623.82
  • S2 1,597.43
  • S3 1,562.87

What's your outlook on Concord Biotech?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Concord Biotech Limited is an R&D-driven biopharma company with two API units and one formulation unit in Gujarat, India. The company supplies APIs and finished formulations across 70+ countries, including the USA, Europe, Japan, and India.

Concord Biotech Ltd has an operating revenue of Rs. 1,089.17 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 40% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 62 which is a FAIR score but needs to improve its earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 44 indicates it belongs to a fair industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Concord Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-13 Quarterly Results
2024-11-11 Quarterly Results
2024-08-09 Quarterly Results
2024-05-23 Audited Results & Dividend
2024-02-08 Quarterly Results
Date Purpose Remarks
2024-06-22 FINAL Rs.8.75 per share(875%)Dividend
View More

Concord Biotech F&O

Concord Biotech Shareholding Pattern

44.08%
4.86%
4.18%
8.33%
7.33%
31.22%

About Concord Biotech

  • NSE Symbol
  • CONCORDBIO
  • BSE Symbol
  • 543960
  • Chairman & Managing Director
  • Mr. Sudhir Vaid
  • ISIN
  • INE338H01029

Similar Stocks to Concord Biotech

Concord Biotech FAQs

Concord Biotech share price is ₹1,650 As on 22 February, 2025 | 21:36

The Market Cap of Concord Biotech is ₹17263.8 Cr As on 22 February, 2025 | 21:36

The P/E ratio of Concord Biotech is 52.9 As on 22 February, 2025 | 21:36

The PB ratio of Concord Biotech is 10.9 As on 22 February, 2025 | 21:36

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23